广州润生细胞医药科技有限责任公司是一家专注细胞医药研发与临床转化研究的中外合资生物科技企业。公司创始人暨学术带头人阮润生教授，瑞士苏黎世大学博士后、新加坡国立大学医学系高级研究员、新加坡科技局生物工程纳米技术研究院首席研究员、欧洲肿瘤内科协会（ESMO）会员，曾入选美国新世纪500名科学家和美国the Marquis’ Who’s Who年鉴。阮润生教授多年来一直致力于细胞免疫学的研发工作，最新研发成果是Tvac ？肿瘤个体化精准联合免疫治疗技术。
公司于2019年9月24日在广州南沙成立，主要从事Tvac ？肿瘤个体化精准联合免疫治疗技术的临床应用探索和开发。相较传统治疗技术，Tvac ？肿瘤个体化精准联合免疫治疗技术通过基因组、蛋白组等组学技术和肿瘤免疫学技术，能够达到个体化精准治疗的目的，是未来肿瘤治疗的重要技术方向。
目前公司已建立生物信息、蛋白组学、多肽合成、细胞免疫四大平台。实验设备方面已配有高速本地服务器及云平台、超高通量106通道多肽合成仪及液相质谱分析仪、PCR仪、Elispot、流式细胞仪、RTCA，细胞培养室等。多维度，全方位的平台建设为新抗原的筛选和多肽药物的研发提供有力的保障和支持，并利用自身平台优势已组建了具备较高专业程度的技术研发团队。团队核心成员来自香港科技大学、丹麦科技大学、美国斯坦福大学医学院、美国哈佛医学院、以及澳大利亚麦考瑞大学等国际***大学及机构，100%硕博学历，主要专业方向是生物信息、肿瘤分子生物学、生物化学、肿瘤免疫学、临床医学和产业化发展等学科。目前，公司已经与新加坡国立大学医院、广东香港科技大学霍英东研究院、中山大学附属***医院、广州医学院第二附属医院、广东省人民医院、广州市第一人民医院等研究机构和医院建立了战略伙伴关系， Tvac？技术正在稳步地开展临床实验探索，项目进展顺利，计划在未来三年内申请Tvac ？的NDA，正式应用于肿瘤的临床治疗。同时，同步开展肿瘤细胞医药其它项目的研发和临床转化研究。
2021年，公司与粤港澳大湾区博士后科技创新（南沙）公共研究中心开展合作，共同打造博士后科研工作站，不断吸纳和培养生物医学高端人才，我们将面向国际为实现行医济世医学梦想的科研人员提供平台。
公司目前以研发人员为主，现有两名外籍专家，组织结构灵活，企业文化清新，是一支拥有国际视野和***水准、朝气蓬勃、干劲十足的细胞医药研发团队。未来，我们将紧贴市场需求，将专业技术应用于广大医疗机构和患者，打造一个集科学发展、人才培养、利益共享的创新科技平台。
Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise focusing on cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, was a postdoctoral fellow at the University of Zurich in Switzerland, a senior researcher at the Department of Medicine of the National University of Singapore, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He was also selected into the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has been committed to the research and development of cellular immunology for many years. His current research and development focus is Tvac？ tumor personalized precision combined immunotherapy technology.
The company was established in Nansha, Guangzhou on September 24, 2019. It is mainly engaged in the exploration and development of clinical application of Tvac？ tumor personalized precision combined immunotherapy technology. Compared with traditional treatment technology, Tvac？ tumor personalized precision combined immunotherapy technology can achieve the purpose of individualized precision treatment through genomics, proteomics and other omics technology and tumor immunology technology, which is an important technical direction for tumor treatment in the future.
At present, the company has established four platforms including bioinformatics, proteomics, peptide synthesis, and cellular immunity. The company is equipped with high-speed local server and cloud platform, ultra-high-throughput 106-channel peptide synthesizer and liquid mass spectrometer, PCR instrument, Elispot, flow cytometer, RTCA, cell culture room, etc. Our multi-dimensional, all-round platform provides strong guarantee and support for the screening of new antigens and the research and development of peptide drugs, and has established a technical research and development team with a high degree of professionalism by using its own platform advantages. The core members of the team come from the Hong Kong University of Science and Technology, the Danish University of Science and Technology, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia and other top international universities and institutions. Our key disciplines include molecular biology, biochemistry, tumor immunology, clinical medicine and industrialization. At present, the company has established collaboration with the National University Hospital of Singapore, the Guangdong Huo Yingdong Research Institute (an affiliate of the Hong Kong University of Science and Technology), the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, Guangzhou First People's Hospital and other research institutions and hospitals. With a strategic partnership, Tvac？ technology is steadily carrying out clinical trials and exploration, and the project is progressing smoothly. It is planned to apply for Tvac？'s NDA in the next three years, which will be formally applied to the clinical treatment of tumors. At the same time, the research and development and clinical translational research of other projects related to tumor cell therapy will be carried out.
In 2021, the company will cooperate with the Postdoctoral Science and Technology Innovation (Nansha) Public Research Center of the Guangdong-Hong Kong-Macao Greater Bay Area to jointly build a post-doctoral research station, and continue to attract and cultivate high-end biomedical talents. We provide a platform for international researchers who will realize the dream of practicing medicine.
The company is currently dominated by R&D personnel, with two foreign experts, flexible organizational structure, and fresh corporate culture. It is a vibrant and energetic cell medicine R&D team with an international vision and top standards. In the future, we will closely follow the needs of the market, apply professional technology to medical institutions and patients, and create an innovative technology platform integrating scientific development, talent training, and benefit sharing.